{"entity":{"id":"elotuzumab","kind":"drug","name":"Elotuzumab","aka":[],"tldr":"An immune-stimulating antibody for myeloma that works only in combination, adding benefit to lenalidomide or pomalidomide.","summary":"Elotuzumab is a monoclonal antibody against SLAMF7 (CS1), a surface protein on both myeloma cells and natural killer cells. It marks myeloma cells for NK-mediated antibody-dependent cellular cytotoxicity and simultaneously activates the NK cells, but it has no single-agent activity and is always combined with an immunomodulatory drug and dexamethasone. ELOQUENT-2 (2015) showed median progression-free survival of 19.4 versus 14.9 months when added to lenalidomide-dexamethasone in patients after 1 to 3 prior therapies, leading to US approval in 2015. ELOQUENT-3 (2018) supported a second approval with pomalidomide-dexamethasone after at least two therapies. CD38 antibodies have largely displaced it, but it remains an option in daratumumab-refractory disease and is generally well tolerated. The key idea is an antibody that works only by recruiting the patient's own immune cells.","status":"approved","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Elotuzumab","links":[{"label":"Label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=elotuzumab"}],"tags":["gap-fill"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["monoclonal-antibody"],"targets":[],"drugs":[],"companies":["bms"],"institutions":[],"pathways":[],"terms":["adcc"],"trials":["nct05730036","nct06152575","nct06158841","nct06208150","nct03989414"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Empliciti","modality":"Anti-SLAMF7 monoclonal antibody","mechanism":"Binds SLAMF7 (CS1) on myeloma cells and NK cells, enhancing NK-mediated ADCC; no single-agent activity.","approvals":[{"region":"US","year":2015,"indication":"Multiple myeloma after 1-3 prior therapies, with lenalidomide-dexamethasone"},{"region":"US","year":2018,"indication":"With pomalidomide-dexamethasone after ≥2 therapies"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/elotuzumab/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}],"term":[{"id":"adcc","kind":"term","name":"ADCC (antibody-dependent cellular cytotoxicity)","route":"/terms/adcc/"}],"trial":[{"id":"nct06208150","kind":"trial","name":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez","route":"/trials/nct06208150/"},{"id":"nct03989414","kind":"trial","name":"A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre","route":"/trials/nct03989414/"},{"id":"nct05730036","kind":"trial","name":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re","route":"/trials/nct05730036/"},{"id":"nct06152575","kind":"trial","name":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other","route":"/trials/nct06152575/"},{"id":"nct06158841","kind":"trial","name":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto","route":"/trials/nct06158841/"}],"target":[{"id":"slamf7","kind":"target","name":"SLAMF7 (CS1)","route":"/targets/slamf7/"}]}}